TY - JOUR
T1 - Lack of insight in schizophrenia
T2 - Impact on treatment adherence
AU - Buckley, Peter F.
AU - Wirshing, Donna A.
AU - Bhushan, Prameet
AU - Pierre, Joseph M.
AU - Resnick, Seth A.
AU - Wirshing, William C.
N1 - Funding Information:
No sources of funding were used to assist in the preparation of this review. Prof. Buckley has received grant/research support from AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen Pharmaceutica, NIMH, Pfizer and Solvay; is a consultant for Abbott, Alamo Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen Pharmaceutica, Pfizer and Merck; and has received honorarium/expenses from Abbott, Alamo Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen Pharmaceutica and Pfizer. Dr Donna Wirshing has received grant/research support from Veteran’s Affairs. Dr Pierre has received grant/research support from NARSAD; is a consultant for AstraZeneca; and is a member of the Speakers’ Bureau for AstraZeneca and Bristol Myers Squibb. Dr William Wirshing has received grant/ research support from Veteran’s Affairs. Drs Bhushan and Resnick have no conflicts of interest to declare.
PY - 2007
Y1 - 2007
N2 - People with schizophrenia commonly lack insight, that is, they are unaware of their illness and the consequences thereof. One of the most important consequences of lack of insight is a failure to recognise the need for treatment, leading to treatment nonadherence. With several scales that now enable objective measurement of insight, it is possible to examine correlates of insight change, including course of illness and treatment adherence. Specific interventions, both pharmacological and psychotherapeutic, have been developed to enhance illness insight and treatment adherence. The extent to which second-generation antipsychotic medications, including a recently released long-acting formulation, improve insight and/or enhance treatment adherence remains to be determined.
AB - People with schizophrenia commonly lack insight, that is, they are unaware of their illness and the consequences thereof. One of the most important consequences of lack of insight is a failure to recognise the need for treatment, leading to treatment nonadherence. With several scales that now enable objective measurement of insight, it is possible to examine correlates of insight change, including course of illness and treatment adherence. Specific interventions, both pharmacological and psychotherapeutic, have been developed to enhance illness insight and treatment adherence. The extent to which second-generation antipsychotic medications, including a recently released long-acting formulation, improve insight and/or enhance treatment adherence remains to be determined.
UR - http://www.scopus.com/inward/record.url?scp=33846967064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846967064&partnerID=8YFLogxK
U2 - 10.2165/00023210-200721020-00004
DO - 10.2165/00023210-200721020-00004
M3 - Review article
C2 - 17284095
AN - SCOPUS:33846967064
VL - 21
SP - 129
EP - 141
JO - CNS Drugs
JF - CNS Drugs
SN - 1172-7047
IS - 2
ER -